Characterizing dynamic regulatory programs in mouse lung development and their potential association with tumourigenesis via miRNA-TF-mRNA circuits

Juan Liu1*, Xinghuo Ye1†, Fang-Xiang Wu2*

From The 6th International Conference on Computational Systems Biology (ISB2012)
Xi'an, China. 18-20 August 2012

Abstract

**Background:** In dynamic biological processes, genes, transcription factors (TF) and microRNAs (miRNAs) play vital regulation roles. Many researchers have focused on the transcription factors or miRNAs in transcriptional or post-transcriptional stage, respectively. However, the transcriptional regulation and post-transcriptional regulation is not isolated in the whole dynamic biological processes, there are few researchers who have tried to consider the network composed by genes, miRNAs and TFs in this dynamic biological processes, especially in the mouse lung development. Moreover, it is widely acknowledged that cancer is a kind of developmental disorder, and some of pathways involved in tissue development might be also implicated in causing cancer. Although it has been found that many genes differentially expressed during mouse lung development are also differentially expressed in lung cancer, very little work has been reported to elucidate the combinational regulatory programs of such kind of associations.

**Results:** In order to investigate the association of transcriptional and post-transcriptional regulating activities in the mouse lung development, we define the significant triple relations among miRNAs, TFs and mRNAs as circuits. From the lung development time course data GSE21053, we mine 142610 circuit candidates including 96 TFs, 129 miRNAs and 13403 genes. After removing genes with little variation along different time points, we finally find 64760 circuit candidates, containing 8299 genes, 50 TFs, and 118 miRNAs in total. Further analysis on the circuits shows that the circuits vary in different stages of the lung development and play different roles. By investigating the circuits in the context of lung specific genes, we identify out the regulatory combinations for lung specific genes, as well as for those lung non-specific genes. Moreover, we show that the lung non-specific genes involved circuits are functionally related to the lung development. Noticing that some tissue developmental systems may be involved in tumourigenesis, we also check the cancer genes involved circuits, trying to find out their regulatory program, which would be useful for the research of lung cancer.

**Conclusions:** The relevant transcriptional or post-transcriptional factors and their roles involved in the mouse lung development are both changed greatly in different stages. By investigating the cancer genes involved circuits, we can find miRNAs/TFs playing important roles in tumour progression. Therefore, the miRNA-TF-mRNA circuits can be used in wide translational biomedicine studies, and can provide potential drug targets towards the treatment of lung cancer.

* Correspondence: liujuan@whu.edu.cn; faw341@mail.usask.ca
† Contributed equally
1 School of Computer, Wuhan University, Wuhan 430072, China
2 Division of Biomedical Engineering, University of Saskatchewan, Saskatoon, SK S7N 5A9, Canada
Full list of author information is available at the end of the article

© 2013 Liu et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Although it is not completely understood what and how many factors play main roles in the process of lung development, several factors that involve in the dynamic process and play important roles have been confirmed by the biologist. Through analysis of gene expression data at different stages of lung development in the field of molecular biology, a series of novel temporal regulations, target genes, transcription factors, and candidate regulatory pathways have been observed during these dynamic biological processes [1,2]. The mammalian lung development can be divided into six stages, ranging from embryos to mature lung [1,3]. At these different stages of lung development, the involved regulatory elements should include both housekeeping and stage-specific ones.

It is well known that transcription factors (TFs) and microRNAs (miRNAs) are key regulators for gene expression regulation in high eukaryotes. The transcription factor play a key role in the transcription process which controls the activity of a gene by determining whether the gene’s DNA is transcribed. The first step of the process of transcription is to convert the gene’s DNA into a complementary coding mRNA molecule; then in the second step, the mRNA molecule is translated as an amino acid sequence of a protein [4]. While, miRNAs are a class of short RNA (21-24 nt) sequences post-transcriptional level [5]. Based on the pairing of miRNAs and their target sites on corresponding mRNAs, the complexes can inhibit translation by either degrading the mRNAs, or by blocking translation without degrading the targets [5].

There have been many studies focusing on investigating the functions of miRNAs or TFs, respectively. For examples, Dong et al. investigated the dynamical miRNA and mRNA regulation patterns for lung development by using statistical and computational methods [6]. Bandypadhyay et al. obtained a global perspective of miRNA dysregulation in multiple cancer types by analyzing the differential expression patterns of specific miRNAs in cancer tissues [7]. There are also some studies considering the miRNA regulatory network [8-10] or TFs and target genes regulatory networks [11]. As a result, many computational tools have been proposed to predict the miRNA–mRNA regulations (EMBL [12], Miranda [13], SNMMNF[14,15], PicTar [16], mirConnX [17], and TargetScan [18]), or the TF–mRNA regulations (TRRD[19], JASPAR[20], and TRANSFAC [21,22]). Recently there are several attempts to discover the combinational links between miRNAs, TFs and target mRNAs (genes) [23-26], however, it is obviously that not enough attention is paid on the regulatory combinations to understand the molecular mechanism of the complicated biological processes. In our preliminary version of this work [27], we have proposed a methodology to consider the regulatory combinations involved in the mouse lung development, and found some regulatory combinations in different lung developmental stages. Our earlier work has only considered the context of lung specific genes. However, the lung developmental process is complicated, which may be involved in not only lung specific but also lung non-specific genes and their regulators. Therefore, not just lung specific genes, but other tissue genes should also be considered to systematically investigate the regulatory mechanism of lung development.

It is widely acknowledged that cancer is a kind of complex developmental disorders, and some controlling developmental systems might also be involved in causing cancer. Lung cancer is the highest mortality cancer [28] and thus has recently attracted more and more attentions. Bonner et al. [29] have examined the genetic changes occurring during lung carcinogenesis by analyzing tissues from mice normal lungs and cancers on Affymetrix U74Av2 gene chips, and found that 24 developmentally regulated genes are aberrantly expressed in lung tumours. Kopantzev et al. [29,30] have found that opposite differences by comparing gene expression profiles in human non-small cell lung carcinomas and in human fetal lung development. Understanding the association of the regulatory mechanisms between lung development and lung tumour might provide novel insight of the lung carcinogenesis, which is helpful for the treatment of the lung cancer.

To address above questions, in this paper we define the significant triple relation among miRNA, TF and mRNA as a circuit, and propose to detect the circuits to identify the non-trivial regulatory combinations in the lung development of mouse. Then we analyze the combinations across the lung development and find out stage-specific combinations. According to the lung specific genes collected from the tissue specific gene database TiSGeD [31], we further distinguish circuits specific to lung development from those irrelevant to the lung developmental process. Finally, we consider the genes that have been shown to be related to cancers in literature and investigate their involved circuitsto find out the multiple roles of miRNAs and TFs in lung development and tumour progression. Our results give a systematic view for understanding the alteration of transcriptional or post-transcriptional regulatory factors and their roles involved in the mouse lung development and tumour progression.

Methods

In this paper, we define the triple relationship among mRNA, TF and miRNA as a circuit (Figure 1) in which the information from transcription and post-transcription is fused to impose and recognize non trivial regulatory
combinations [32]. Based on the definition, we integrate information on miRNAs, TFs, genes, and their interactions to detect and investigate the circuits related to the biological process (Figure 2).

Data resources

(1) Lung development time-course data collected from two mouse samples: GSE21053 [6]. GSE21053 consists of GSE20152 and GSE20954, corresponding to miRNA and gene expression data respectively. The expression values are measured at seven time points: embryo day 12, 14, 16, and 18; and postnatal day 2, 10 and 30.

(2) Lung specific genes: The Tissue-Specific Genes Database (TiSGeD) [31]. TiSGeD provides comprehensive information of genes specific to lung and other tissues collected from biomedical literatures. By setting SPM [31] threshold as 0.3, we extract 511 lung specific genes from TiSGeD, 455 of them are in common with GSE20954 and will be used for further study.

(3) Cancer related genes: we collect all the 487 cancer related genes from Cancer Gene Census[33], 118 of which are overlapped with the lung developmental genes, and 19 of which are also found to be lung specific genes.

(4) miRNA-gene pairs: miRanda [34], TargetScan [18] and circuitDB [35].

(5) TF-gene pairs: KEGG [36], Tred [37] and circuitDB [35].

(6) miRNA-TF pairs: circuitDB [35].
Extraction of miRNA-TF-mRNA circuit candidates

The flowchart of extracting miRNA-TF-mRNA circuit candidates is shown in Figure 3. First, we extract miRNAs from GSE20152, TFs and genes from GSE20954 (we just use the coding genes to represent the TFs in this work). We preprocess gene expression data by filtering out those with small variances along all seven time points. As a result, there remain 8299 genes for further study. Then we extract miRNA-gene, TF-gene and miRNA-TF pairs from the data described above. All pairs are combined into potential miRNA-TF-mRNA circuits. As a result, we find 64760 circuit candidates, containing 8299 genes, 50 TFs and 118 miRNAs in total.

Detection of significant circuits relevant to lung development

For each pair \( <i, j> \) in a circuit candidate (\( i \) and \( j \) are two vectors of expression data along a period of time points), we evaluate the significance of the pair-wise relationship at a specific stage of lung development by using Pearson correlation coefficient \( R(i, j) \):

\[
R(i, j) = \frac{E[(i - \mu_i)(j - \mu_j)]}{\sqrt{E[(i - u_i)^2]E[(j - u_j)^2]}}
\]

where \( E \) is the mathematical expectation and \( \mu_i \) is the mean of vector \( i \). We use the permutation test to evaluate the significance of the correlation and set the p-value threshold as 0.05. Only when all of three pairs in the same circuit candidate are significant, can it be regarded as a circuit at the specific period of lung development.

Results and discussion

Figure 4 displays the result obtained by two-way clustering genes along 7 time points of the mouse lung development. It can be seen that the mouse lung development is mainly gone through two stages. The first stage is from time point 1 to time point 3 and the second stage is from time point 4 to time pint 7. We notice that although time points 1-4 correspond to embryo days 12, 14, 16 and 18, time point 4 is grouped with time points 5-7 (postnatal days 2, 10 and 30). Thus we can envision that the
molecular mechanism of pseudoglandular and canalicular of lung (embryo days 12-17) is very different with that of saccular and alveolar (≥ embryo day 17) which continues until a period of time after birth (postnatal days 2, 10, and 30). Furthermore, we have found that time point 7 (postnatal day 30) are different with time points 4-6 though they are grouped together, which may be due to the fact that postnatal day 30 corresponds to the maturation at the microvasculature stage. Therefore, we only consider time points 1-3 and 4-6 of the lung development and respectively call them as early and late stages hereinafter.

From 64760 collected circuit candidates, we have mined 1046 circuits including 10 TFs, 574 genes and 19 miRNAs in the early stage, and 195 circuits including 7 TFs, 147 genes and 13 miRNAs in the late stage. To see how the circuits change across the lung development, we have also mined 3201 circuits involved in the whole six time points of the lung development, including 13 TFs, 1565 genes and 28 miRNAs. Figure 5 illustrates the overlap circuits among the early, late and whole stages. It can be seen that there are different circuits involved at different stages, which means that the roles of TFs/miRNAs/genes within the circuits vary greatly during the lung development, and they involve in different biological pathways at different stages.

Dynamic circuits involved in the lung development

The circuits in the early and late stages of the lung development are shown in Figure 6 (see Additional file 1 for the details). We can see that different circuits involve in different stages. Even for those common miRNAs/TFs/genes, they participate in different circuits in two stages, showing that they may play varied roles during the lung development. For example, at the early stage the target genes of miRNA mir-135b are Arhgef9, Car3, Ccdc88a, Cth, Dcx, Efnb3, Faah, Gabra4, Ints2, Mrps25, Ms4a6d, Myo18a, Pcdh18, Pus1, Sip1, Tnpo1, and Wdhd1. However, at the late stage the target genes of miRNA mir-135b are changed to Ccdc88a, Cdh10, Cth, Pcdhb3, Rnf138, Tpc6, and Ttyh2.

We further plot the expression profiles of common miRNAs/TFs/genes in Figure 7 to show the variations of their activities. From Figure 7 we can also see that the miRNAs/TFs/genes may be involved in different function modules in different stages.

TF overlap (Figure 5(b))

We have found that there are four TFs: BACH2, IRF1, MYC and HOXA4, which are participated in the early and late stages. BACH2 and HOXA4 are down-regulated in the early stage and up-regulated in the late stage (HOXA4 is one point time lagged); and IRF1 is up-regulated while MYC is down-regulated across all
It has been shown that Hox genes are implicated in the lung development and the patterning, and the HOXA4 and HOXA5 are likely to be involved in the patterning of the mouse lung [38]. According to the GO term GO:0048513, IRF1 and MYC also have the function related to the organ development. It is noticeable that MYC amplification is found to be a prognostic marker of early-stage lung adenocarcinoma [39], and BACH2 has also been researched in the cancer treatment [40], which shows that the tumour has association with the developmental process.

**MiRNA overlap (Figure 5(c))**

We have found that there are five miRNAs participated in both the early and late stages: mmu-mir-200a, mmu-mir-200b, mmu-mir-135b, mmu-mir-494 and mmu-mir-503. They show similar expression profiles along six time points of the lung development: first down-regulated and then up-regulated (Figure 7(b)). The miR-200 family is believed to play an essential role in the tumour suppression. It has been shown to play an important role in fibrotic lung diseases [41]. The mir-135b, mir-503b and mir-94 are also found to have relationship with lung cancer.
We think that miRNAs related to cancers may more likely participate in regulatory programs of both lung developmental stages.

**Gene overlap (Figure 5(d))**

We have found that there are 24 common genes roughly divided into two groups (Prdx6, B3gnt2, Car3, Cbx1, Ccde88a, Cdh13, Cpeb1, Cth, Dclkl, Dnajc9, Fgd4, Il1rap, Ip09, Klf4, Khl29, Mpp7, Pde7a, Pdk4, Per1, Phf20, Plat, Rnf138, Rtn4, Tdrkh) occurring in the early and late stages (Figure 7(c)). It has been shown that most of them are related to tumours, such as Prdx6 [45], Cdh13 [46], Klf4 [47], and so on. Once again, we suggest that common genes in early and late stages of lung development may be more likely related to tumourigenesis even if they are not shown to be cancer genes.

**Dynamic regulations of circuits in the context of lung specific genes**

Reinvestigating Figure 6 in the context of the lung specific genes, we have found that not only are lung specific but also non-specific genes related to the lung development (their involved circuits are shown in Figure 8 and Figure 9, respectively).

Specifically, we have detected out some regulators for lung non-specific genes, i.e., TF: ATF6, DBP (early), and TBP (late); miRNAs: mmu-mir-152, mmu-mir-187, mmu-mir-320, mmu-mir-326, mmu-mir-451 (early), and mmu-mir-494 (late). We think that they should have functions related to the lung development even though their regulating genes are not lung specific. For examples, ATF6 is an endoplasmic reticulum (ER) stress-regulated transmembrane transcription factor, and specific ER stress signaling transmitted by ATF6 leads to naturally occurring apoptosis during the muscle development [48]; DBP is a multifunctional protein found in plasma, ascitic fluid, cerebrospinal fluid, and urine and on the surface of many cell types; miR-320 plays a role in neuronal development[49]. According to the functional annotations of the regulators, it seems that they can actually play roles in the lung development in an indirect way.

To analyze the dynamic regulations in different stages of the lung development, we have constructed the
circuit network of the common TFs, miRNAs and gene in different lung development stages, in the context of lung specific genes (as shown in Figure 10).

From Figure 10, we can see that different group of genes involved in early and late stages of the lung development, regulated by different TF-miRNA combinations. Moreover, some common genes/TFs/miRNAs involved in different stages show different functions. Gene Prdx6 is involved in one circuit in the early stage (IRF1~mmu-mir-503~Prdx6), while involved in the other two circuits containing the
**Figure 8** The lung specific genes involved circuits at different stages. Circuits in red and green rectangles are of early and late stages respectively, and circle, square and triangle nodes stand for miRNAs, TFs and genes respectively.

**Figure 9** Lung non-specific genes involved circuits. TF and miRNA in dashed yellow circle box are in lung development circuit network but not are included in lung tissue specific circuit network.
same miRNA (MYC~mmu-mir-19a~Prdx6, IRF1~mmu-mir-19a~Prdx6) in the late stage. Thus, in different stages of the lung development, Prdx6 may show different functions which are mainly determined by mmu-mir-503 and mmu-mir-19a, respectively.

We have also noted that mmu-mir-200a play some roles in the early stage by cooperating with MEIS1, while play other roles in the late stage by cooperating with BRCA1 together. By cooperating with different miRNAs, transcript factors BACH2, MYC or IF1 can co-regulate different genes in the early and late stages, respectively.

**Functional specificities of circuits in lung development**

We have found that the miRNA and the TF usually have dynamical regulation programs at different stages during mouse lung development. In particular, the involved genes usually have opposite expression profiles at different stages (Figure 4). To computationally explore the potential functions of the dynamically regulated genes in lung development, we have employed biological process and pathway analysis on the lung specific genes.

Using DAVID tool [50], we get all enriched biological processes (Table 1) and pathways (Table 2) (P-value < 0.05). From Table 1, we have found several GO terms relevant to lung development. For example, three GO terms related to phosphorus function involve in the early stage: GO:0006793 GO:0006796 and GO:0016310. As known to all, inorganic phosphate (Pi) plays a critical role in diverse cellular functions and low Pi affects the lung development of mice by disturbing protein translation [51]. The GO:0051094 (positive regulation of developmental process) and GO:0035023 (regulation of Rho protein signal transduction) are also very relevant to the lung development. Rho protein plays a significant role in inhibiting lung development [52] while the ROCK2 plays a major role in the formation of the gas exchange units and as a sensor for accelerating the lung development [53,54].

In Table 2, the pathways indicated in bold have been reported to be associated with lung. For mmu04810, Actin cytoskeleton plays a role in human pulmonary artery ECS [55]. For mmu00740, lung remodelind induced by exposure of total parenteral nutrition to ambient light is due to the interaction between vitamin C and peroxides generated by the exposure of riboflavin to light [56]. For mmu04060, the analysis of lung adenocarcinoma tissue specimens have demonstrated that the
genes involved in these biological pathways have high rates of over-expression [57]. For mmu00230, metabolic changes in the lung as a result of ventilation-induced lung injury are reflected by an increased level of purine in the bronchoalveolar lavage fluid and that purine may, thus, serve as an early marker for ventilation-induced lung injury [58]. For mmu00533, the pathways of Keratan sulphate biosynthesis are associated with prostate cancer and small cell lung cancer[59].

### Investigation on cancer genes involved in circuits

As it is known to all, the developmentally regulated genes may be involved in lung tumours. Therefore we pick out the circuits related to the cancer genes from Figure 4 (shown in Figure 11). From Figure 11, we have identified out the regulating miRNAs and TFs of the 118 cancer genes and found out there are 38 circuits including 7 TFs, 14 miRNAs and 25 genes at the early stage; 6 circuits with 2 TFs, 4 miRNAs and 4 genes at the late stage. Any abnormal expression of the regulatory combinations may result in tumour. Compared to the cancer genes, the number of miRNAs/TFs is obviously smaller, which makes it more convenient to the research or treatment of cancer. From Figure 11, we have further extracted those lung specific genes involved circuits (shown in Figure 12), which contain 5 genes, 1 TFs and 6 miRNAs. We have noticed that miRNAs are from mir-200 family (mir-200a, mir-200b and mir-429), mir-29 family (mir-29a and mir-29c) and mir-150 family, they are all related to lung cancer[60,61]. Specifically, miR-200 miRNAs are involved in cancer metastasis[62]; mir-150 functions in hematopoiesis, and regulates genes whose downstream products encourage differentiating stem cells towards becoming megakaryocytes rather than erythrocytes [63]; mir-29 miRNAs activates p53, the tumour suppressor [64]. MEIS1 is a conserved transcription factor of the TALE-homeodomain class, expressed in a wide variety of tissues during development, and known to be required for the development of many organs in vertebrates and invertebrates. It has also been found incorrectly expressed in a number of tumour types, such as acute myeloid leukemia [65], lung adenocarcinoma tumours [66], nephroblastomas [67], and so on. Therefore, the circuits shown in Figure 12 uncevers that the regulatory combinations of MEIS1 and mir-200/mir-29/mir-150 miRNAs play roles in the early stage in the lung development, while their abnormal expressions may result in the tumour progression.

| Table 1 Top 10 GO biological process terms in different periods |
|------------------|-----------------|-----------------|
| Period           | NO  | Term                                    | P-value        |
| Early            | 1   | GO:0006793--phosphorus metabolic process | 5.40E-05       |
|                  | 2   | GO:0006796--phosphate metabolic process  | 5.40E-05       |
|                  | 3   | GO:0016310--phosphorylation              | 1.21E-04       |
|                  | 4   | GO:0045596--negative regulation of cell differentiation | 2.60E-04 |
|                  | 5   | GO:0051056--regulation of small GTPase mediated signal transduction | 3.32E-04 |
|                  | 6   | GO:0006468--protein amino acid phosphorylation | 5.28E-04 |
|                  | 7   | GO:0035023--regulation of Rho protein signal transduction | 5.30E-04 |
|                  | 8   | GO:0007167--enzyme linked receptor protein signaling pathway | 7.96E-04 |
|                  | 9   | GO:0022604--regulation of cell morphogenesis | 0.001564 |
|                  | 10  | GO:0051094--positive regulation of developmental process | 0.002006 |
| Late             | 1   | GO:0006928--cell motion                  | 7.08E-05       |
|                  | 2   | GO:0016477--cell migration               | 0.001009       |
|                  | 3   | GO:0030030--cell projection organization  | 0.002595       |
|                  | 4   | GO:0017148--negative regulation of translation | 0.002614 |
|                  | 5   | GO:0010558--negative regulation of macromolecule biosynthetic process | 0.00269 |
|                  | 6   | GO:0010608--posttranscriptional regulation of gene expression | 0.002856 |
|                  | 7   | GO:0032268--regulation of cellular protein metabolic process | 0.003146 |
|                  | 8   | GO:0031327--negative regulation of cellular biosynthetic process | 0.003426 |
|                  | 9   | GO:0048870--cell motility                | 0.003474       |
|                  | 10  | GO:0051674--localization of cell         | 0.003474       |

| Table 2 Significant pathways in different periods |
|------------------|-----------------|-----------------|
| Period           | No  | Term                                    | P-value        |
| Early            | 1   | mmu04512:ECM-receptor interaction       | 0.005104       |
|                  | 2   | mmu04810:Regulation of actin cytoskeleton | 0.006057       |
|                  | 3   | mmu04115:p53 signaling pathway          | 0.014693       |
|                  | 4   | mmu05200:Pathways in cancer             | 0.028372       |
|                  | 5   | mmu00740:Riboflavin metabolism          | 0.030496       |
|                  | 6   | mmu04060:Cytokine-cytokine receptor interaction | 0.036709 |
| Late             | 1   | mmu00230:Purine metabolism              | 0.011819       |
|                  | 2   | mmu00533:Keratan sulfate biosynthesis   | 0.013904       |
Figure 11 Dynamic circuits related to cancer genes. Circuits in red and green dashed box are of early and late stages respectively, and circle, square and triangle nodes stand for miRNAs, TFs and genes.

Figure 12 Lung specific cancer genes involved circuits showing the association between lung development and tumourigenesis.
Conclusions
In this work, we have mined and investigated the miRNA-TF-mRNA circuits in mouse lung development. The results have shown that the relevant transcriptional or post-transcriptional factors and their roles involved in lung development greatly vary at different stages. By considering those circuits associated with lung specific genes, we have identified out the dynamic regulatory interaction of miRNA-TF-mRNA circuits in different lung development stages. By investigating the circuits in the context of cancer genes, we have detected out some circuits related to the lung cancer, thus illustrating the association between the lung development and the tumourigenesis. Therefore, the miRNA-TF-mRNA circuits can be used in wide translational biomedicine studies, and can provide potential drug targets towards the treatment of lung cancer.

Additional material

Additional file 1: The excel file for the circuits shown in Figure 6.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Liu initiated the main idea of the paper and supervised the whole work. Ye conducted all of the programming and computational experiments. Liu, Ye and Wu discussed about this study. The manuscript was written by Liu and Ye, and revised by Liu, Ye and Wu.

Acknowledgements
A preliminary version of this paper was published in the proceedings of IEEE ISB012.

Declarations
The publication of this article has been funded by the National Science Foundation of China (61272274, 60970063), the program for New Century Excellent Talent in Universities (NCET-10-0644), the PH.D. Programs Foundation of Ministry of Education of China (20090141110026) and the Fundamental Research Funds for the Central Universities (60810007).

Authors’ details
1 School of Computer, Wuhan University, Wuhan 430072, China. 2 Division of Biomedical Engineering, University of Saskatchewan, Saskatoon, SK S7N 5A9, Canada.

Published: 17 December 2013

References
1. Bonner AE, Lemon WJ, You M. Gene expression signatures identify novel regulatory pathways during murine lung development: implications for lung tumorigenesis. Journal of medical genetics. 2003, 40(6):408-417.
2. Weng T, Chen Z, Jin N, Gao L, Liu L. Gene expression profiling identifies regulatory pathways involved in the late stage of rat fetal lung development. American journal of physiology. Lung cellular and molecular physiology. 2006, 291(5):1027-1037.
3. Ten Hove-Oopbroek AA. Lung development in the mouse embryo. Experimental lung research. 1991, 17(2):111-130.
4. Vaqueras JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nature reviews Genetics. 2009, 10(4):252-263.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136(2):215-233.
6. Dong J, Jiang G, Asmann YW, Tomaszek S, Jen J, Kålånger T, Wigle DA. miRNA networks in mouse lung organogenesis. PLoS one 2010, 5(5):e10854.
7. Bandypadhyay S, Mitra R, Maulik U, Zhang MQ. Development of the human cancer microRNA network. Silence. 2010, 1(16).
8. Volinia S, Galano M, Castellano S, Tagliavini L, Gambonetti G, Druso A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010, 20(5):589-599.
9. Rubio-Somoza I, Weigel D. MicroRNA networks and developmental plasticity in plants. Trends in plant science. 2011, 16(5):258-264.
10. Olde Loohuis NF, Kos A, Martens GI, Van Bokhoven H, Nadif Kasri N, Aschrafi A. MicroRNA networks direct neuronal development and plasticity. Cellular and molecular life sciences. CMLS. 2012, 69(13):189-192.
11. Liu J, Liu ZJ, Pan YC, Liu Q, Fu X, Cooper NG, Li Y, Ouy M, Shi T. Regulatory module network of basic/helix-loop-helix transcription factors in mouse brain. Genome biology. 2007, 8(11):R244.
12. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolution. Curr. Biol. 2005, 15(6):1113-1116.
13. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic acids research 2008, 36(Database):D149-153.
14. Zhang SH, Li QJ, Liu J, Zhou JX. A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules. Bioinformatics. 2011, 27(Suppl 2):S11-S19.
15. Zhang S, Liu C, Li W, Shen H, Laird PW, Zhou XJ. Discovery of multidimensional modules by integrative analysis of cancer genomic data. Nucleic acids research. 2012, 40(19):9579-9591.
16. Lall S, Grun D, Krek A, Chen K, Wang YI, Dewey CN, Soo P, Colombo T, Bray N, Macmenamin P, et al. A genome-wide map of conserved microRNA targets in C. elegans. Current biology. 2006, 16(5):460-471.
17. Huang GT, Athanassiou C, Benos PV. mirConnX: condition-specific mRNA-microRNA network integrator. Nucleic acids research 2011, 39(Web Server):W416-423.
18. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian miRNAs are conserved targets of microRNAs. Genome research. 2009, 19(12):162-165.
19. Stepanenko I, Kolchanov N. Apoptosis gene network: description in the GeneNet and TRRD databases. Annals of the New York Academy of Sciences. 2003, 1010:16-18.
20. Portales-Casamar E, Thongue S, Kwon AT, Arenillas D, Zhao X, Valen E, Yusuf D, Lenhard B, Wasserman WW, Sandelin A. JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic acids research. 2010, 38(Database):D105-D110.
21. Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Briefings in bioinformatics. 2008, 9(4):326-332.
22. Peter ME. Targeting of miRNAs by multiple miRNAs: the next step. Oncogene. 2010, 29(15):2161-2164.
23. Re A, Cora D, Tavenna D, Caselle M. Genome-wide survey of microRNA-transcription factor feed-forward regulatory circuits in human. Molecular bioSystems. 2009, 5(B):854-867.
24. Eduati F, Di Camillo B, Karbiener M, Scheidelier M, Cora D, Caselle M, Toffolo G. Dynamic modeling of miRNA-mediated feed-forward loops. Journal of computational biology: a journal of computational molecular cell biology. 2012, 19(2):188-199.
25. Brosh R, Shalgi R, Liran A, Landan G, Korotayev A, Nguyen GH, Enery E, Johnsen H, Buganim Y, Solomon H, et al. p53-Regulated microRNAs are involved with E2F1 in a feed-forward loop promoting proliferation. Molecular systems biology. 2008, 4:229.
26. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005, 435(7043):859-863.
27. Ye XY, Liu J, Wu FX. Dynamic microRNA-TF-mRNA circuits in mouse lung development. 2012 IEEE 6th International Conference on Systems Biology (ISB):18-20 Aug, Xian, China IEEE press, 2012, 256-262.
28. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A cancer journal for clinicians. 2012, 62(1):10-29.
29. Bonner AE, Lemon WJ, Devereux TR, Lubet RA, You M: Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene 2004, 23(5):1166-1176.

30. Kapantzev EP, Monastyrskaya GS, Vinogradova TV, Zinovyeva MV, Kostra MB, Filbyova KB, Toneyavtovs AG, Sukhlit GT, Sverdlov ED: Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer 2008, 62(1):23-34.

31. Xiao SJ, Zhang C, Zou Q, Ji ZL. TISGeD: a database for tissue-specific genes. Bioinformatics 2010, 26(9):1273-1275.

32. Ye X, Liu J, Wu F-X. Dynamic miRNA-TF-mRNA circuits in mouse lung development. 2012 IEEE 6th International Conference on Systems Biology (SB); 2012, 256-262.

33. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR: A census of human cancer genes. Nature reviews Cancer 2004, 4(3):177-187.

34. Betel D, Kopp A, Aguas P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology 2010, 11(8):R90.

35. Friard O, Re A, Taverna D, De Bortoli M, Cora D: CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse. BMC Bioinformatics 2010, 11:435.

36. Tanabe H, Koshida T. Using the KEGG Database Resource. Current protocols in bioinformatics/editorial board, Andreas D Baxevanis [et al] 2012, Chapter 1, Unit 12.

37. Zhao F, Xuan Z, Liu L, Zhang MQ: The Journal of cell biology transmitted by ATF6 mediates apoptosis during muscle development.

38. Packer AI, Mailutha KG, Ambrozewicz LA, Wolgemuth DJ: MiR-320a and miR-494 is regulated by ERK1/2 and modulates effects of anticancer drugs. Blood 2003, 102(9):3317-3322.

39. Iwakawa R, Kohno T, Kato M, Shirashe K, Tsuta K, Noguchi M, Ogawa S, Yokota J. MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clinical cancer research: an official journal of the American Association for Cancer Research 2011, 17(6):1481-1489.

40. Kamio T, Toki T, Kanekazi R, Sakai S, Tanzai S, Terui K, Ikeda I, Igarashi K, Ito E. B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. The American journal of pathology 2011, 178(3):1028-1037.

41. Bourdon JA, Saber AT, Halappanavar S, Jackson PA, Wu D, Hougaard KS, Ito E. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 2006, 100(3):996-1002.

42. Cloutier M, Tremblay M, Pichard B: ROCK2 is involved in accelerated fetal lung development induced by in vivo lung distension. Pediatric pulmonology 2010, 45(6):966-976.

43. McIver LK, Bauer NR, Fagan KA, Nagaoka T, Gepp SB, Oka M: Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Advances in experimental medicine and biology 2003, 543:127-137.

44. Urayuk PV, Romer LH, De H, Parinandi NL, Kleinberg ME, Zhan S, Jacobson JR, Dudek SM, Pendladya S, Garcia JG, et al. Regulation of hypoxia-induced NAPDH oxidase activation in human lung endothelial cells by the actin cytoskeleton and cortactin. The Journal of biological chemistry 2007, 282(32):25284-25295.

45. Lavelle JC, Boulon T, Chevallier J. Interaction between ascorbate and light-exposed riboflavin induces lung remodeling. The Journal of pharmacology and experimental therapeutics 2004, 311(2):634-639.

46. Chang MY, Yu VP, Tsai JR, Sheu CC, Chong IW, Lin SR: Combined olingouneucleotide microarray-bioinformatics and constructed membrane arrays to analyze the biological pathways in the carcinogenesis of human lung adenocarcinoma. Oncology reports 2007, 18(3):569-579.

47. Verbrugghe SJ, de Jong JW, Keijzer E, Vazquez de Anda G, Lachmann B: Purine in bronchoalveolar lavage fluid as a marker of ventilation-induced lung injury. Critical care medicine 1999, 27(4):779-783.

48. He K, Wang Q, Yang Y, Wang M, Pan Y: A Comparative Study of Mouse Hepatic and Intestinal Gene Expression Profiles under PPARalpha Knockout by Gene Set Enrichment Analysis. PPAR research 2011, 2011:629738.

49. Li J, Szekely L, Eriksson L, Heddson B, Sundbom A, Czene K, Hall P, Humphreys K: High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer. Breast cancer research: BCR 2012, 14(1):R14.

50. Zhang XK, Sun JG, Sun J, Ming H, Wang XX, Wu L, Chen ZT: Prediction of radiation pneumonitis in lung cancer patients: a systematic review. Journal of cancer research and clinical oncology 2012, 138(12):2103-2116.

51. Grell P, Fabian P, Khlyou M, Radova L, Slaby O, Hrstka R, Vytula R, Hajduch M, Svoboda M: Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. International journal of oncology 2012.

52. Stekema J, Boart H, Alemann BM, Wessels LF, van Sandick JW: Prognostication and prediction using gene expression profiling in oesophageal cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2012.

53. Chen HC, Kodeil RL, Cheng KF, Chen RJ: Assessment of performance of survival prediction models for cancer prognosis. BMC medical methodology 2012, 12:102.

54. Zhang Y, Sun Y, Xiang J, Hu H, Chen H: A prediction model for N2 disease inT1 non-small cell lung cancer. The Journal of thoracic and cardiovascular surgery 2012, 144(6):1360-1364.

55. Kim W, Kim KS, Lee JE, Noh DY, Kim SW, Jung YS, Park MY, Park RW: Development of novel breast cancer recurrence prediction model using support vector machine. Journal of breast cancer 2012, 15(2):220-238.

56. Sun T, Simon L, Moreno V, Roeper P, Tabernero J, Snel M, Van’t Veer L, Salazar R, Remonds R, Capella G: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2012.